3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
OTHER
1
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
4
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Advanced Solid Tumours
2
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Diseases
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Endometrial Neoplasms
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Carboplatin
99
Pemetrexed
71
pembrolizumab
69
Cisplatin
60
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
ceralasertib
×
Clear all
NCT05450692
2026-04-16
LATIFY
AstraZeneca
Phase 3
Active not recruiting
594 enrolled
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled